An agreement to develop and market orally administered insulin products, which might total as much as $238 million, has been signed by GlaxoSmithKline of London and Nobex Corporation of Research Triangle Park, North Carolina.
Under the terms of the agreement, GlaxoSmithKline will pay a fee up-front to Nobex, with additional payments related to product development, manufacturing and marketing.
The first product, which is in phase 1 and 2 clinical trials, is a modified oral insulin designed to control post-meal blood-glucose levels. The process uses a technology that allows the insulin to be rapidly absorbed into the bloodstream. “Nobex oral insulin is absorbed across the intestinal wall and follows a similar pathway as insulin normally released by the pancreas,” the companies said in a news release.